What therapy would you offer a young BRAF wild type patient with metastatic melanoma, who progressed on single agent pembrolizumab?

Given that response to anti-PD-1 therapy is one of the strongest biomakers for outcome in patients with metastatic melanoma, prognosis for these patients is poor. Therefore, clinical trial should be strongly considered, if available.

If no clinical trial is available, standard options for these pati...